We are live on ! Find out more
RUBY

Rubius Therapeutics

Delisted

RUBY was delisted on the 6th of March, 2023.

57 hedge funds and large institutions have $1.11B invested in Rubius Therapeutics in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

704% more capital inflows, than outflows

Capital inflows: $95.1M | Capital outflows: $11.8M

54% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 13

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

5.86% more ownership

Funds ownership: 81.75% → 87.61% (+5.9%)

4% more funds holding

Funds holding: 55 → 57 (+2)

Holders
57
Holders Change
+2
Holders Change %
+3.64%
% of All Funds
1.26%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
12
Increased
20
Reduced
13
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

RUBY Hedge Fund Activity: Q4 2018 in Review

57 of the 4,507 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics (RUBY) for Q4 2018, worth a combined $1.11B — down 28% from $1.54B a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new RUBY positions and 10 closed out — a net gain of 2 holders — while 20 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $15.3M. The largest seller was Capital International Investors, cutting an estimated $3.1M.

  • 57 institutional investors held Rubius Therapeutics (RUBY) as of Q4 2018, up from 55 in Q3 2018.
  • Funds reported $1.11B of Rubius Therapeutics stock for Q4 2018, down 28% quarter-over-quarter.
  • 12 funds opened new Rubius Therapeutics positions in Q4 2018 and 10 closed out, a net change of +2 holders.
  • The largest Rubius Therapeutics buyer in Q4 2018 was BlackRock, an estimated $15.3M added.
  • The largest Rubius Therapeutics seller in Q4 2018 was Capital International Investors, an estimated $3.1M sold.

Based on aggregated 13F filings for Q4 2018.